Artiva Biotherapeutics is an immunotherapy company focused on developing off-the-shelf, allogeneic NK cell therapies for patients with autoimmune diseases and cancers. Their lead program, AlloNK®, is designed to enhance the activity of monoclonal antibodies or NK cell engagers and is currently in clinical trials for the treatment of systemic lupus erythematosus (SLE) and Non-Ho...Show More